ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed for AdenoVerse Immunotherapy for Recurrent Respiratory Papillomatosis
March 30, 2021Precigen announced the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP). -
Precigen Receives Orphan Drug Designation for PRGN-AdenoVerse™ Immunotherapy for Respiratory Papillomatosis
March 24, 2021Precigen announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).
Pharma Sources Insight January 2025
